THE UK’S drug regulator has warned doctors of the ‘small risk of severe acute pancreatitis’, a potentially fatal condition, in patients taking weight‑loss and diabetes drugs linked to around two deaths per week in the UK. Meanwhile, Novo Nordisk, maker of Ozempic, faces more than 1,800 lawsuits alleging the drug has caused not only acute pancreatitis but also stomach paralysis, vision loss, kidney injury, gallbladder disease and other permanent harms. If successful, the claims could cost the company up to $2billion.
